Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany encouraged by Pfizer COVID-19 vaccine news, cautious on timeline

Mon, 09th Nov 2020 11:28

* Health ministry does not expect first vaccines before Q1
2021

* Spahn says need 55-65% of population to get vaccinated

* German experts set out first guidelines on priority groups
(Adds details from news conference with German health minister)

BERLIN, Nov 9 (Reuters) - Germany's health minister is
encouraged by a Pfizer announcement that its COVID-19
vaccine proved effective in a late-stage trial but still does
not expect a shot to be available before the first quarter of
2021, he said on Monday.

Pfizer and its German partner BioNTech said on
Monday their experimental vaccine was more than 90% effective in
preventing COVID-19 based on initial data from a large study, a
major victory in the fight against the pandemic.

"If this should prove true ... then it would be a good
signal because it shows that this vaccine makes a difference,"
Jens Spahn told a news conference, but added he was cautious on
the timeline because there can always be setbacks.

To break the dynamic of the spread of the coronavirus,
between 55% and 65% of the population will need to be
vaccinated, Spahn said. However, the first vaccines are only
expected to be available in limited amounts.

Germany plans to set up centralised vaccination centres to
inoculate priority groups in the first instance, which will be
supported by mobile teams.

First in line for vaccines should be those who are at risk
due to their age or pre-existing conditions, particularly people
living in nursing homes or long-term care facilities, the German
research centre Leopoldina and the Ethics Council said in a
position paper on priorities for vaccine delivery on Monday.

The second group should include those exposed to the virus
through their jobs, such as front-line healthcare workers, who
could also spread infections to vulnerable people.

For the third group, the experts proposed those who are
needed to maintain public life, including health authority
officials, police and security staff, firefighters and teachers.

Detailed recommendations will only be possible once
late-stage data on the characteristics of vaccines is available,
the experts said.

The German health ministry expects seven potential vaccines
to complete testing this year or next, and is anticipating the
first approvals in the first quarter of 2021, according to a
copy of its national vaccine strategy paper seen by Reuters.

Vaccination will not be mandatory. The German government
will pay for the vaccines, while the cost of setting up
vaccination centres will be borne by the states and public and
private health insurers where appropriate.

To get an overview on the effectiveness of the vaccines,
Germany will collect non-personal data including information on
age, sex, place of residence, vaccination date, vaccine product
and vaccination dose administered, the ministry paper says.
(Reporting by Andreas Rinke and Caroline Copley; Editing by
Maria Sheahan, Michelle Adair and Jan Harvey)

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.